Is This a Drug Deal or a Rights Offering?

Bookmark
(Bloomberg Opinion) -- What happens when strategic ambition meets financial constraint? The answer is found in AstraZeneca Plc’s $6.9 billion oncology tie-up with Japan’s Daiichi Sankyo Co. Ltd.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.